Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...

Pills are displayed with open pill bottles on top of a white counter top in the kitchen.Viking Therapeutics (VKTX) released ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

The best of Australia’s travel industry has been named in the National Travel Industry Awards. The banquet hall at the ...

Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment.

On Friday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $78.03 which represents a slight increase of $4.81 or 6.57% from the prior close of $73.22. The stock opened at ...

On Thursday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $73.22 which represents a slight increase of $12.83 or 21.25% from the prior close of $60.39. The stock opened ...

That's more than enough to cover its operating cash burn, which over the trailing 12 months has totaled just under $72 million. Even if its rate of cash burn accelerates, Viking looks to have ...

Viking Therapeutics, Inc. (VKTX) closed at $65.85 in the latest trading session, marking a +0.72% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%.